ClinicalTrials.gg
CompletedNCT03332732Updated Oct 18, 2018

VNRX-5133 Drug-Drug Interaction in Healthy Adult Volunteers

A Phase 1 interventional study of VNRX-5133 and VNRX-5022 in Bacterial Infections, sponsored by Venatorx Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-18.

Sponsored by Venatorx Pharmaceuticals, Inc. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Dec 2017, 8 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 181 studies in Bacterial Infections with a site in United States — 12 open to participants now, 15 under way, 2 of them phase 3. Bacterial Infections · United States.

Enrollment
98th of 151
42 · median 62
Started
2017
with 13 others
Phase 1
66 of 181
2 open now
Registered
118th of 181
by date

Among the 181 studies in Bacterial Infections with a site in United States, this one is the 98th largest by enrollment of the 151 interventional ones that give a count, is one of 14 that started in 2017, is one of 66 in phase 1, and was the 118th registered.

Bacterial Infections

585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

12 of the 181 studies in Bacterial Infections with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 181 studies in Bacterial Infections with a site in United States, or all of them as a file.
02

Study summary

This is a 2-part, drug-drug interaction study to evaluate potential PK interactions after single doses in Part 1 and multiple doses in Part 2. In Part 1, subjects will receive single dose of 5 treatments in a cross-over design; in Part 2 subjects will receive treatment for 10 days.

03

Conditions studied

  • Bacterial Infections

Browse trials for

Keywords

  • Healthy Volunteers
  • Pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults
  • Males or non-pregnant, non-lactating females
  • (BMI) between 18.5 - 32.0, inclusive
  • Weight greater than or equal to 50 kg
  • Suitable veins for cannulation

Exclusion criteria

Exclusion Criteria:

  • Employee of site or the sponsor
  • Any disease that poses an unacceptable risk to participants
  • Abnormal
  • Abnormal labs
  • Abnormal vital signs
  • Current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, , hematologic, neoplastic, or neurological disorder
  • Positive serology for surface antigen, antibody, or (HIV) type 1
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Part 1A

    In Part 1A, subjects will receive single doses of VNRX-5133 and VNRX-5022 alone and in combination. All subjects will receive all treatments in the sequence specified by the randomization schedule..

    Drug: VNRX-5133 · Drug: VNRX-5022

  • Experimental
    Part 1B

    In part 1B, subjects from Part 1A will receive metronidazole with or without VNRX-5133 + VNRX-5022. All subjects will receive all treatments in the sequence specified by the randomization schedule.

    Drug: VNRX-5133 · Drug: VNRX-5022 · Drug: Metronidazole

  • Experimental
    Part 2 - 2A

    Multiple dose administration of Low Dose VNRX-5133 + VNRX-5022

    Drug: VNRX-5133 · Drug: VNRX-5022

  • Experimental
    Part 2 - 2B

    Multiple dose administration of High Dose VNRX-5133 + VNRX-5022

    Drug: VNRX-5133 · Drug: VNRX-5022

  • Placebo comparator
    Part 2 - 2C

    Multiple dose administration of Placebo (matching VNRX-5133 + VNRX-5022)

    Drug: Placebo

Interventions

  • β-lactamase inhibitor

  • Approved β-lactam antibiotic

  • Approved antibiotic and antiprotozoal medication

  • DrugPlacebo

    Placebo (matching VNRX-5133 + VNRX-5022)

06

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration (Cmax) of VNRX-5133 and VNRX-5022 following single doses alone and in combination (Part 1A)

    Cmax

    Time frame: 0-48 hours

  2. Area under the plasma concentration versus time curve (AUC) of VNRX-5133 and VNRX-5022 following single doses alone and in combination (Part 1A)

    AUCinf

    Time frame: 0-48 hours

Secondary outcomes

  1. Peak Plasma Concentration (Cmax) of metronidazole, VNRX-5133, and VNRX-5022 (Part 1B)

    Cmax

    Time frame: 0-48 hours

  2. Area under the plasma concentration versus time curve (AUC) of metronidazole, VNRX-5133, and VNRX-5022 (Part 1B)

    AUCinf

    Time frame: 0-48 hours

  3. Number of Subjects with Treatment Emergent Adverse Events

    TEAEs based on patient reporting, physical exams, collection of vital signs, ECGs and absolute values and changes over time of hematology, chemistry and urinalysis.

    Time frame: First dose to 7 days after last dose: Part 1: 20 days / Part 2: 17 days

  4. Accumulation of VNRX-5133 + VNRX-5022 following multiple dose administration

    Trough concentration levels from Day 1 - Day 10

    Time frame: Part 2: 10 days

Other outcomes

  1. Bactericidal titers (Part 2)

    To evaluate serum and urine bactericidal activity at peak and trough concentrations following multiple dose administration of VNRX-5133 + VNRX-5022

    Time frame: 10 days

07

Study locations

1 site
  • PRAHS
    Lenexa, Kansas 66219, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Dec 2017, 1 month.

Of 52 industry-sponsored phase 1 interventional studies under Bacterial Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 1 month is below that.

Counting every sponsor, half of 67 studies reached it within 9 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2017
First posted
Nov 6, 2017
StartActual
Oct 24, 2017
Primary completionActual
Dec 20, 2017
CompletionActual
Dec 20, 2017
Last update
Oct 18, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03332732
Lead sponsor
Venatorx Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Nov 6, 2017
Start date
Oct 24, 2017
Primary completion
Dec 20, 2017
Completion
Dec 20, 2017
Last update
Oct 18, 2018

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Taniborbactam

Start the discussion